Use of disease risk scores in pharmacoepidemiologic studies

被引:106
|
作者
Arbogast, Patrick G. [1 ]
Ray, Wayne A. [2 ,3 ]
机构
[1] Vanderbilt Univ, Dept Biostat, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Dept Prevent Med, Nashville, TN 37232 USA
[3] Nashville Vet Adm, Med Ctr, Ctr Geriatr Res Educ & Clin, Nashville, TN 37232 USA
基金
美国医疗保健研究与质量局;
关键词
NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROPENSITY SCORE; STRATIFICATION; DEATH;
D O I
10.1177/0962280208092347
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Automated databases are increasingly used in pharmacoepidemiologic studies. These databases include records of prescribed medications and encounters with medical care providers from which one can construct very detailed Surrogate measures for both drug exposure and covariates that are potential confounders. Often it is possible to track day-by-day changes in these variables. However, while this information is often critical for study success, its Volume can pose challenges for statistical analysis. One common approach is the use of propensity scores. An alternative approach is to construct a disease risk score. This is analogous to the propensity score in that it calculates a summary measure from the covariates. However, the disease risk score estimates the probability or rate of disease Occurrence conditional oil being unexposed. The association between exposure and disease is then estimated adjusting for the disease risk score in place of the individual covariates. This review describes the use of disease risk scores in phamacoepidemiologic studies, and includes a brief discussion of their history, a more detailed description of their construction and use, a summary of simulation Studies comparing their performance vis-a-vis traditional models, a comparison of their utility with that of propensity scores, and some further topics for future research.
引用
收藏
页码:67 / 80
页数:14
相关论文
共 50 条
  • [31] EVALUATION OF THE RELIABILITY AND VALIDITY OF A MEASURE OF ANXIOLYTIC DRUG-USE INTENSITY FOR PHARMACOEPIDEMIOLOGIC STUDIES
    RIED, LD
    JOHNSON, RE
    ANNALS OF PHARMACOTHERAPY, 1992, 26 (11) : 1441 - 1446
  • [32] GENETIC RISK SCORES AND CORONARY HEART DISEASE RISK
    Bloch, Michael J.
    JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 2015, 9 (08) : 580 - 581
  • [33] Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis
    Kay, Jonathan
    Bock, Amy E.
    Rehman, Muhammad
    Zhang, Wuyan
    Zhang, Min
    Iikuni, Noriko
    Alvarez, Daniel F.
    RMD OPEN, 2022, 8 (02):
  • [34] Assessing the Use of the Estimand Framework in Recent Pharmacoepidemiologic Post-market Safety Studies
    Liu, Wei
    Mayo, Susan
    Ma, Yong
    Haddad, Jonathan
    Bennett, Dimitri
    Snyder, Ellen S.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 416 - 417
  • [35] Clinical use of polygenic risk scores for detection of peripheral artery disease and cardiovascular events
    Omiye, Jesutofunmi A.
    Ghanzouri, Ilies
    Lopez, Ivan
    Wang, Fudi
    Cabot, John
    Amal, Saeed
    Ye, Jianqin
    Lopez, Nicolas Gabriel
    Adebayo-Tijani, Faatihat
    Ross, Elsie Gyang
    PLOS ONE, 2024, 19 (05):
  • [36] Mapping Of Existing Disease-Specific Data Sources For The Conduct Of Pharmacoepidemiologic Studies In China
    Yuen, Chung Yan
    Bergamasco, Aurore
    Arredondo-Bisono, Teigna
    Moride, Yola
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 606 - 607
  • [37] Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies
    Lai, Edward Chia-Cheng
    Pratt, Nicole
    Hsieh, Cheng-Yang
    Lin, Swu-Jane
    Pottegard, Anton
    Roughead, Elizabeth E.
    Yang, Yea-Huei Kao
    Hallas, Jesper
    EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2017, 32 (07) : 567 - 582
  • [38] Selection bias due to immigration in pharmacoepidemiologic studies
    Stovring, Henrik
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 (06) : 681 - 686
  • [39] Use of risk scores in acute coronary syndromes
    Bueno, Hector
    Fernandez-Aviles, Francisco
    HEART, 2012, 98 (02) : 162 - 168
  • [40] Diabetes risk scores: use in diabetes prevention
    Schiborn, Catarina
    Schulze, Matthias B.
    DIABETOLOGE, 2020, 16 (03): : 226 - 233